Issued on behalf of Avant Technologies Inc.
VANCOUVER – USA News Group News Commentary – Just weeks after the groundbreaking $500-billion announcement of Project Stargate, which aims to redefine the future of healthcare, industry leaders are increasingly recognizing the potential of Artificial Intelligence (AI). According to a recent Deloitte survey, 40% of healthcare executives report that generative AI (genAI) is already delivering tangible benefits for their businesses. As 2025 unfolds, genAI is proving to be a game-changer in diagnostics, treatment advancements, and personalized medicine. While Project Stargate has sparked a lot of talk regarding the AI healthcare revolution, a wave of emerging innovators is making significant strides in AI-driven healthcare solutions, with notable updates from Avant Technologies, Inc. (OTCQB: AVAI), Workday, Inc. (NASDAQ: WDAY), Butterfly Network, Inc. (NYSE: BFLY), iCad, Inc. (NASDAQ: ICAD), and VSee Health, Inc. (NASDAQ: VSEE).
The article continued: AI’s influence is expanding rapidly, with analysts at BCC Research forecasting that the AI Revolutionizing Industries Market will experience a 39.7% CAGR, reaching an estimated $1.1 trillion by 2029. Meanwhile, research from SNS Insider projects that the Generative AI in Healthcare Market—valued at $1.7 billion in 2023—is set to skyrocket to $19.99 billion by 2032, growing at a robust 31.5% CAGR.
Avant Technologies and Ainnova Advance Toward FDA Clinical Trial with Selection of Top CRO
Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, and its partner, Ainnova Tech, a leading healthcare technology company focused on revolutionizing early disease detection using AI, today announced the selection of Fortrea, a global provider of clinical development solutions to the life sciences industry, as the contract research organization (CRO) to conduct Ainnova’s upcoming clinical studies to seek approval from the U.S. Food and Drug Administration (FDA) for Ainnova’s Vision AI platform.
Fortrea will assist Ainnova in requesting a pre-submission meeting with the FDA for guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy. After a pre-submission meeting, Fortrea will then work with Ainnova on its FDA submission and a subsequent clinical study before concluding with an FDA 510(k) submission to obtain clearance from the FDA to market its Vision AI platform.
The upcoming clinical studies are significant to Avant and its shareholders because of the partnership formed by Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio, including its Vision AI platform and its versatile retinal cameras. The joint venture formed by the two companies, Ai-nova Acquisition Corp. (AAC), has the licensing rights for this portfolio in the U.S., Canada, and Europe, so the success of Ainnova’s clinical studies with the FDA will be vital to marketing the technology portfolio in the United States.
“We worked diligently to identify and select the right CRO to help us both engage the FDA and then conduct our clinical studies,” said Vinicio Vargas, CEO of Ainnova regarding the selection. “Fortrea is an established and highly regarded full-service CRO with expertise in more than 20 therapeutic areas, and a CRO with an extensive portfolio of successfully completed clinical trials, including those involving both emerging and large biopharmaceutical, medical device, and diagnostic companies.”
With Fortrea’s guidance, Ainnova expects to submit its pre-submission application in the coming weeks and expects to meet with the FDA for its pre-submission meeting in late March/early April 2025.
Additionally, Ainnova will also interact with the FDA to devise a plan to obtain clearance for four algorithms it recently acquired the exclusive licensing rights to, which include early detection for cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease, and chronic kidney disease.
Late last year, Avant announced a game-changing collaboration with pharma giant Roche, highlighting Avant’s ability to partner with global healthcare leaders and leverage its innovative technologies for real-world impact. Together with Ainnova and Salud 360, Avant set forth to launch a pilot program to combat diabetic retinopathy has been launched in Costa Rica. This initiative uses VisionAI to automate retinal image analysis, identifying early disease markers and facilitating timely interventions. If successful, the program aims for broader adoption in the United States, Canada, and Europe through AAC.
“At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system,” said, Alvaro Soto, General Manager of Roche Central America, Caribbean, and Venezuela. “By leveraging technology, we seek to improve lives, optimize diagnoses, and ensure that every patient has access to timely and effective treatment. With this model, we not only seek to address the problem of diabetic retinopathy, but also to establish a replicable path for other diseases that require innovative solutions.”
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Other recent industry developments and happenings in the market include:
Workday, Inc. (NASDAQ: WDAY), a leading provider of solutions to help organizations manage their people and money, to help employees maximize their health and financial benefits, recently announced a strategic partnership with Nayya, the leading source connecting Americans’ health and wealth data to deliver personalized guidance. Through this strategic partnership, Workday and Nayya will set an industry standard in powering health and wealth decisions through Built on Workday – a program that empowers Workday partners to build, manage, and deploy apps on the Workday platform.
“Nayya is transforming the benefits experience by providing employees with the personalized guidance needed to make better, more informed decisions about their health and financial wellness,” said Mark David, vice president of partner innovation, Workday. “Nayya is a true innovator in this space and by integrating Nayya’s platform into Built on Workday, we will empower organizations to deliver a differentiated employee experience and drive better business results.”
Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound recently announced preliminary findings from a seminal study conducted by Rutgers Robert Wood Johnson Medical School (RWJMS) and Robert Wood Johnson University Hospital (RWJUH), an RWJBarnabas Health facility, demonstrating the transformative impact of point-of-care ultrasound (POCUS) on patient outcomes and hospital efficiency. A late-breaking clinical trial presentation of the data was disseminated at the European Association of Cardiovascular Imaging’s EchoEuro-Imaging Conference in Berlin, Germany in December 2024.
The study found that using cardiopulmonary POCUS devices for hospital patients with unexplained shortness of breath significantly reduced hospital stays and costs. Patients saw their length of stay drop by over four days on average, with higher-acuity cases improving from 39 to 16.7 days and cost savings reaching up to 50%.
“These results reflect the immense value of POCUS in enhancing care delivery and reducing the financial burden of hospitalizations,” said Dr. John Martin, Chief Medical Officer, Butterfly Network. “The integration of POCUS into hospital workflows is not just about advancing technology but about transforming the patient experience while addressing critical challenges in healthcare systems.”
iCad, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, presented four novel AI-driven breast cancer research abstracts back in December at the 2024 San Antonio Breast Cancer Symposium (SABCS). The clinical abstracts highlighted the latest research in breast health AI, focusing on improving detection and risk prediction accuracy and assessing disparities across diverse populations.
“These studies exemplify the critical role the ProFound AI Breast Health Suite can play in not only improving early breast cancer detection and risk prediction but also in addressing health disparities in diverse populations,” said Dana Brown, President and CEO of iCAD. “We are proud to collaborate with Solis Mammography and Karolinska Institute contributing to groundbreaking research that can elevate the standard of care in breast health worldwide. These partnerships demonstrate the potential of our technology to improve patient outcomes, and also opens pathways to broader adoption of AI in healthcare, driving growth in key markets.”
VSee Health, Inc. (NASDAQ: VSEE), a leader in comprehensive digital health services and customized telehealth solutions, recently announced the successful renewal of a $2 million, two-year contract with a top 50 Integrated Delivery Network (IDN) hospital system. This renewal significantly expands the partnership, doubling the number of covered hospital beds and incorporating VSee Health’s autonomous self-driving robot solutions for neurocritical care.
The renewed partnership underscores the growing demand for autonomous healthcare technologies and seamless telehealth integrations in critical care settings. VSee Health’s self-driving robot solutions will enable real-time patient monitoring, provider collaboration, and AI-assisted care workflows—empowering hospitals to manage higher patient volumes without straining their existing workforce.
“We are proud to deepen our collaboration with one of the nation’s top health systems, delivering a scalable and intelligent telehealth solution that improves patient outcomes while optimizing hospital operations,” said Imo Aisiku, M.D., Co-CEO of VSee Health. “This renewal solidifies the effectiveness of our comprehensive digital health stack and reinforces our commitment to shaping the future of remote and automated healthcare.”
CONTACT:
USA NEWS GROUP
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
